Daniel Schneiderman's Insider Trades & SAST Disclosures
Daniel Schneiderman's most recent trade in Pasithea Therapeutics Corp was a trade of 10,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on March 1, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Daniel Schneiderman.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Pasithea Therapeutics Corp | Daniel Schneiderman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Pasithea Therapeutics Corp | Daniel Schneiderman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Pasithea Therapeutics Corp | Daniel Schneiderman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 5,927 | 5,927 | - | - | Stock Option (right to buy) | |
| Pasithea Therapeutics Corp | Daniel Schneiderman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 5,927 | 5,927 | - | - | Stock Option (right to buy) | |
| Pasithea Therapeutics Corp | Daniel Schneiderman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Oct 2022 | 300,000 | 300,000 | - | - | Stock Option (to acquire Common Stock) | |
| First Wave BioPharma Inc | Daniel Schneiderman | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 10,000 | 10,000 | - | - | Stock option (right to buy) | |
| First Wave BioPharma Inc | Daniel Schneiderman | CHIEF FINANCIAL OFFICER | Other type of transaction at price $ 0.00 per share. | 30 Jun 2021 | 250,000 | 0 | - | - | Stock option (right to buy) | |
| First Wave BioPharma Inc | Daniel Schneiderman | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 250,000 | 250,000 | - | - | Stock option (right to buy) | |
| First Wave BioPharma Inc | Daniel Schneiderman | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 35,006 | 35,006 | - | - | Stock option (right to buy) | |
| First Wave BioPharma Inc | Daniel Schneiderman | CHIEF FINANCIAL OFFICER | Other type of transaction at price $ 0.00 per share. | 30 Jun 2021 | 35,006 | 0 | - | - | Stock option (right to buy) | |
| First Wave BioPharma Inc | Daniel Schneiderman | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jul 2020 | 250,000 | 250,000 | - | - | Stock option (right to buy) | |
| First Wave BioPharma Inc | Daniel Schneiderman | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jul 2020 | 35,006 | 35,006 | - | - | Stock option (right to buy) | |
| First Wave BioPharma Inc | Daniel Schneiderman | CHIEF FINANCIAL OFFICER | Other type of transaction at price $ 0.00 per share. | 16 Jul 2020 | 35,006 | 300,000 | - | - | Stock option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges